News|Articles|May 15, 2017

Pharmaceutical Technology

  • Pharmaceutical Technology-05-15-2017
  • Volume 2017 eBook
  • Issue 1

Case Study: Retrofitting Two New High-Purity Water Systems

The existing, obsolete highpurity water generation system and water-forinjection generation system were replaced with new, reliable technologies.

GlaxoSmithKline (GSK)’s R&D Biopharmaceutical Pilot Plant in Upper Merion, PA is a R&D clinical trial material (CTM) manufacturing facility with an aggressive processing schedule that requires minimal shutdown interruptions. Utility reliability is paramount to achieve production demands and regulatory quality requirements.

To meet the utility demands for increased CTM output, a capital investment project was required to replace the existing, obsolete high purity water (HPW) generation system and water-for-injection (WFI) generation system with new, reliable technology.

This article describes how the new systems were designed and installed in a challenging space to ensure redundancy and improve sustainability.

Download

Pharmaceutical Technology’s 2017 Biologics and Sterile Drug Manufacturing eBook

.

 

 


Related to this article

Ask the Expert: Choosing Ingredient Suppliers
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.